Figure 7
(A) Effect of GB235 and Trastuzumab on KPL-4 xenograft. SCID mice bearing KPL-4 tumors were randomized into four groups when tumor volumes reached 100∼200 mm3 (n = 6 mice/each group). The KPL-4 xenograft was intraperitoneally injected with GB235 (30 mg/kg), Trastuzumab (30 mg/kg), combination treatment of GB235 (30 mg/kg) and Trastuzumab (30 mg/kg), or negative control. *p < 0.05. (B) For the patient-derived tumor xenograft GA0060 model, when the tumor volume was approximately 100 mm3 (n = 5 mice/group), the nude mice were treated with Trastuzumab (10 mg/kg) or in combination with GB235 (10 + 20 mg/kg). Tra: Trastuzumab. Data are presented as the mean tumor volume ± SEM. ***p < 0.001.
